Oral and parenteral iron drugs in patients with severe iron deficiency anemia

А. В. Зайченко, Д. В. Лыткин

Abstract


Treatment of iron deficiency anemia include the elimination of the root causes of iron loss (liquidation hemorrhage, treatment of major diseases), diet rich in heme and iron, and use of mono- or combination preparations of iron.

For initial treatment of iron deficiency are used oral ferrous drugs, which contain iron in the bivalent (ionic) or trivalent (non-ionic) form.

In emergency conditions where oral iron preparations cannot quickly recover iron deficiency, iron preparations are administered parenteral, and preferred dosage form is intravenous administration.

Numerous clinical studies have shown that the drug Venofer® (iron sucrose (III)) for intravenous administration is more effectively restore hematocrit level, serum ferritin and erythropoiesis than other parenteral and oral iron preparations.


Keywords


iron deficiency anemia; oral iron preparations; parenteral iron preparations; Venofer®

References


Anastasevich, L.A., Malcoch, A.V. “Iron deficiency anemia in infants and young children.” Attending Physician, 7(2006): published online. Last accessed Sept 06, 2015.

R ecommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep, 47 (RR-3) (1998): 1–29.

Gorodetsky, V.V., Godulyan, O.V. Iron deficiency and iron deficiency anemia: diagnostics and treatment (Methodical recommendations). Moscow. Medpractice-M (2006): 28 p.

Dvoretsky, L.I. “Hypochromic anemia.” Gematology, 9 (Vol. 3) (2001).

Zakharova, I.N., Dmitrieva, Y.A. “The syndrome of anemia in pediatric practice: differential diagnosis and therapy.” Effective Pharmacotherapy. Pediatrics, 3(2011): 40–47.

Kaye, P., Abdullah, K., Wood, J., James, P., et al. “Iron-induced pathology of upper gastrointestinal tract: characteristic observation in patients receiving oral iron therapy.” Health of Ukraine, 1(13) (2014): 20–22.

Kolosova, N.G. “Iron deficiency anemia in infants.” Pediatrics, 04(2013): published online. Last accessed Sept 06, 2015.

Okorokov, A.N. Diagnostics of internal organs diseases. Vol. 4. Diagnostics of blood system diseases. Moscow. Medical literature (2001): 512 p.

Sarsania, S.I., Tikhomirov, A.L., Nochevkin, E.V., Touskaev, K.S. “Nuances of diagnostics and treatment of iron deficiency anemia.” Difficult Patient, 02(2012): published online. Last accessed Sept 06, 2015.

Sokur, T.N., Dubrovina, N.V., Fedorova, Y.V. “The principles of prevention and treatment of iron deficiency anemia in pregnant women.” Consilium medicum, 2 (Vol. 9) (2007).

Tarasova, I.S. “Iron deficiency anemia in children and adolescents.” Current Pediatrics Issues, 2(10) (2011): 40–48.

Tatvidze, M.L., Khvedelidze, V.A. “Impact of nutritional factors on the development of iron deficiency.” Herald SEUA , “Chemical and environmental technology”. 2 (Issue 15) (2012).

Tikhomirov, A.L., Sarsania, S.I., Nochevkin, E.V. “Some aspects of diagnostics and treatment of iron deficiency states in practice at the present stage.” Difficult Patient, 11(2011): published online. Last accessed Sept 06, 2015.

Tsvetkova, O.A. “Medical and social aspects of iron deficiency anemia.” Russian Medical Journal, 5(2009): 387–391.

Shalina, R.I., Kutakova, Y.Y., Breusenko, L.I., et al. “Assessment of the effectiveness of the drug Venofer in iron deficiency states after obstetric hemorrhage.” Questions of Gynecology, Obstetrics and Perinatology, 1(3) (2004): 37–42.

Fisher, A.E.O., Naughton, D.P. “Iron supplements: the quick fix with long-term consequences.” Nutr J, 3(2) (2004).

A ronoff, G.R., Bennett, W.M., Blumenthal, S., Charytan, C., et al. “Iron sucrose in hemodialysis patients: Safety and efficacy of iron replacement and maintenance therapy.” Kidney Int, 66(2004):1193–1198.

A uerbach, M., Ballard, H., Glaspy, J. et al. “Clinical update: intravenous iron for anaemia.” Lancet, 369(2007): 1502–1504.

Beshara, S., Lundqvist, H., Sundin, J., et al. Pharmacokinetic analysis and red cell utilization of 52Fe/59Fe labelled iron (III) hydroxide sucrose complex following intravenous administration using positron emission tomography. Clinical study report (1997). American Regent, Inc. Shirley. New York.

Bodnar, L.M., Scanlon, K.S., Freedman, D.S., et al. “High prevalence of postpartum anemia among low income women in the United States.” American Journal of Obstetrics and Gynecology, 185(2001): 438–443.

C harytan, C., Quinibi, W., Bailie, W. “Comparison of Intravenous Iron Sucrose to Oral Iron in the Treatment of Anemic Patients with Chronic Kidney Disease Not on Dialysis.” Nephron Clin Pract, 100(2005): 55–62.

E uropean Parliament. “Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use.” Official Journal L, 136(47) (2004): 34–57.

Heath, A.L., Fairweather-Tait, S.J. “Clinical implications of changes in the modern diet: iron intake, absorbtion and status.” Best Practical & Reasearch Clin Haem, 2 (Vol. 15) (2002): 225–241.

Instructions for use of the drug Venofer®.

W orld Health Organization. Iron deficiency anemia assessment, prevention and control. A guid for programme managers. Geneva. WHO (2001). [http:// www.who.int/nutrition/publications/en/ida_assessment_ prevention_control.pdf], last accessed Sept 9, 2015.

M acdougall, I., Bailie, G., Richardson, D., Tanner, J., Gagnon, S.P. “Worldwide safety profile of iron sucrose injection (Venofer): analysis of 1,044,477 patients from 1992 to 2001.” J Am Soc Nephrol, 12(2001): 333A.

R evised European Best Practice Guidelines for the Management of anemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant, 19 (Suppl. 2) (2004): 2–45.

R ogler, G., Vavricka, S. “Anemia in inflammatory bowel disease: an under-estimated problem?” Front Med Lausanne, 1(2015): 58.

R ottembourg, J., Kadri, A., Leonard, E., et al. “Do two intravenous iron sucrose preparations have the same efficacy?” Nephrol Dial Transplant, 26(10) (2011): 3262–3267.

Schellekens, H., Klinger, E., Mhlebach, S., et al. “The therapeutic equivalence of complex drugs.” Regul Toxicol Pharmacol, 59(2011): 176–183.

W orld Health Organization. The prevalence of anemia in women: a tabulation of available information. Second edition. Geneva. WHO (1992). [http:// apps.who.int/iris/bitstream/10665/58994/1/WHO_MCH_ MSM_92.2.pdf], last accessed Sept 9, 2015.

W orld Health Organization. The World Health Report. 22. Screening for Iron Deficiency Anemia – Including Iron Prophilaxis. Recommendation. Geneva. WHO (1998). [http://www.ncbi.nlm.nih.gov/books/ NBK15471/?report=reader], last accessed Sept 9, 2015.

T oblli, J.E., Cao, G., Giani, J., et al. “Different effects of European iron sucrose similar preparations and originator iron sucrose on nitrosative stress, apoptosis, oxidative stress, biochemical and inflammatory markers in rats.” XLVIII ERA EDTA Congress (2011).

Van Wyck, D.B., et al. “A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non-dialysis dependent CKD.” Kidney Int, 68(2005): 2846–2856.

Yip, R. “Iron deficiency: contemporary scientific issues and international programmatic approaches.” Journal of Nutrition Bethesda, 85 (Vol. 124) (1994): 1479–1490.


GOST Style Citations


1. Железодефицитная анемия у детей грудного и младшего возраста / Л.А. Анастасевич, А.В. Малкоч / Лечащий врач. — 2006. — № 7. [http://www.lvrach. ru/2006/07/4534190/], дата последнего обращения 06.09.2015.

2. R ecommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep, 47 (RR-3) (1998): 1–29.

3. Городецкий, В. В. Железодефицитные состояния и железодефицитные анемии: диагностика и лечение (Методические рекомендации) / В. В. Городецкий, О. В. Годулян // — М., Медпрактика-М. — 2006. — 28 с.

4. Дворецкий, Л.И. Гипохромные анемии. — Гематология. — 2001. — № 9, Т. 3.

5. Захарова, И.Н. Синдром анемии в практике педиатра: дифференциальная диагностика и терапия / И.Н. Захарова, Ю.А. Дмитриева // Эффективная фармакотерапия. Педиатрия. — 2011. — № 3. — С. 40–47.

6. Кайе, П., Абдулла, К., Вуд, Дж., Джеймс, П. и др. Железо-индуцированная патология верхних отделов желудочно-кишечного тракта: характерное наблюдение у пациентов, получающих пероральную терапию препаратами железа / П. Кайе, К. Абдулла, Дж. Вуд, П. Джеймс, С. Фолей, К. Рагунат, Дж. Атертон // Здоровье Украины. — 2014. — № 1 (13). — С. 20–22.

7. Колосова, Н.Г. Железодефицитная анемия у детей раннего возраста / Н.Г. Колосова // Педиатрия. — 2013. — 04. [http:// www.con-med.ru/magazines/pediatry/pediatry-04-2013/ zhelezodefitsitnaya_anemiya_u_detey_rannego_vozrasta], дата последнего обращения 06.09.2015.

8. Окороков, А.Н. Диагностика болезней внутренних органов. Том 4. Диагностика болезней системы крови. — М., Медицинская литература. — 2001. — 512 с.

9. Сарсания, С.И. Нюансы диагностики и лечения железодефицитной анемии / С.И. Сарсания, А.Л. Тихомиров, Е.В. Ночевкин, К.С. Тускаев // Трудный пациент. — 2012. — 02. [http://t-pacient.ru/articles/461/], дата последнего обращения 06.15.2015.

10. Сокур Т.Н. Принципы профилактики и лечения железодефицитных анемий у беременных / Т.Н. Сокур, Н.В. Дубровина, Ю.В. Федорова // Consilium medicum. — 2007. — № 2, Т. 9.

11. Тарасова, И.С. Железодефицитная анемия у детей и подростков / И.С. Тарасова // Вопросы современной педиатрии. — 2011. — № 2 (10). — С. 40–48.

12. Татвидзе, М.Л. Влияние алиментарного фактора на развитие железодефицитных состояний / М.Л. Татвидзе, В.А. Хведелидзе // Вестник ГИУА. Серия «Химические и экологические технологии». — 2012. — № 2, Вып. 15.

13. Тихомиров, А.Л. Некоторые аспекты диагностики и лечения железодефицитных состояний в практической деятельности на современном этапе / А.Л. Тихомиров, С.И. Сарсания, Е.В. Ночевкин // Трудный пациент. — 2011. — 11. [http://t-pacient.ru/articles/6725/], дата последнего обращения 06.09.2015.

14. Цветкова, О.А. Медико-социальные аспекты железодефицитной анемии / О.А. Цветкова // Русский медицинский журнал. — 2009. — № 5. — С. 387–391.

15. Шалина, Р.И. Оценка эффективности применения препарата Венофер при железодефицитных состояниях после акушерских кровотечений / Р.И. Шалина, Ю.Ю. Кутакова, Л.И. Бреусенко и др. // Вопросы гинекологии, акушерства и перинатологии. — 2004. — № 1 (3). — С. 37–42.

16. Fisher, A.E.O., Naughton, D.P. “Iron supplements: the quick fix with long-term consequences.” Nutr J, 3(2) (2004).

17. A ronoff, G.R., Bennett, W.M., Blumenthal, S., Charytan, C., et al. “Iron sucrose in hemodialysis patients: Safety and efficacy of iron replacement and maintenance therapy.” Kidney Int, 66(2004):1193–1198.

18. A uerbach, M., Ballard, H., Glaspy, J. et al. “Clinical update: intravenous iron for anaemia.” Lancet, 369(2007): 1502–1504.

19. Beshara, S., Lundqvist, H., Sundin, J., et al. Pharmacokinetic analysis and red cell utilization of 52Fe/59Fe labelled iron (III) hydroxide sucrose complex following intravenous administration using positron emission tomography. Clinical study report (1997). American Regent, Inc. Shirley. New York.

20. Bodnar, L.M., Scanlon, K.S., Freedman, D.S., et al. “High prevalence of postpartum anemia among low income women in the United States.” American Journal of Obstetrics and Gynecology, 185(2001): 438–443.

21. C harytan, C., Quinibi, W., Bailie, W. “Comparison of Intravenous Iron Sucrose to Oral Iron in the Treatment of Anemic Patients with Chronic Kidney Disease Not on Dialysis.” Nephron Clin Pract, 100(2005): 55–62.

22. E uropean Parliament. “Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the community code relating to medicinal products for human use.” Official Journal L, 136(47) (2004): 34–57.

23. Heath, A.L., Fairweather-Tait, S.J. “Clinical implications of changes in the modern diet: iron intake, absorbtion and status.” Best Practical & Reasearch Clin Haem, 2 (Vol. 15) (2002): 225–241.

24. Инструкция по применению препарата Венофер®.

25. W orld Health Organization. Iron deficiency anemia assessment, prevention and control. A guid for programme managers. Geneva. WHO (2001). [http:// www.who.int/nutrition/publications/en/ida_assessment_ prevention_control.pdf], last accessed Sept 9, 2015.

26. M acdougall, I., Bailie, G., Richardson, D., Tanner, J., Gagnon, S.P. “Worldwide safety profile of iron sucrose injection (Venofer): analysis of 1,044,477 patients from 1992 to 2001.” J Am Soc Nephrol, 12(2001): 333A.

27. R evised European Best Practice Guidelines for the Management of anemia in Patients with Chronic Renal Failure. Nephrol Dial Transplant, 19 (Suppl. 2) (2004): 2–45.

28. R ogler, G., Vavricka, S. “Anemia in inflammatory bowel disease: an under-estimated problem?” Front Med Lausanne, 1(2015): 58.

29. R ottembourg, J., Kadri, A., Leonard, E., et al. “Do two intravenous iron sucrose preparations have the same efficacy?” Nephrol Dial Transplant, 26(10) (2011): 3262–3267.

30. Schellekens, H., Klinger, E., Mhlebach, S., et al. “The therapeutic equivalence of complex drugs.” Regul Toxicol Pharmacol, 59(2011): 176–183.

31. W orld Health Organization. The prevalence of anemia in women: a tabulation of available information. Second edition. Geneva. WHO (1992). [http:// apps.who.int/iris/bitstream/10665/58994/1/WHO_MCH_ MSM_92.2.pdf], last accessed Sept 9, 2015.

32. W orld Health Organization. The World Health Report. 22. Screening for Iron Deficiency Anemia – Including Iron Prophilaxis. Recommendation. Geneva. WHO (1998). [http://www.ncbi.nlm.nih.gov/books/ NBK15471/?report=reader], last accessed Sept 9, 2015.

33. T oblli, J.E., Cao, G., Giani, J., et al. “Different effects of European iron sucrose similar preparations and originator iron sucrose on nitrosative stress, apoptosis, oxidative stress, biochemical and inflammatory markers in rats.” XLVIII ERA EDTA Congress (2011).

34. Van Wyck, D.B., et al. “A randomized controlled trial comparing IV iron sucrose to oral iron in anemic patients with non-dialysis dependent CKD.” Kidney Int, 68(2005): 2846–2856.

35. Yip, R. “Iron deficiency: contemporary scientific issues and international programmatic approaches.” Journal of Nutrition Bethesda, 85 (Vol. 124) (1994): 1479–1490.





DOI: http://dx.doi.org/10.18370/2309-4117.2015.24.30-36

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

ISSN 2411-1295 (Online), ISSN 2309-4117 (Print)